Portola Pharmaceuticals, Inc. Discovering and developing novel therapeutics.
Descrizione della società:
portola pharmaceuticals is a biopharmaceutical company developing innovative drugs for the treatment of cardiovascular and inflammatory diseases portolaõs two most advanced programs are in phase ii clinical trials: 1) betrixaban, an oral, once-daily factor xa inhibitor being developed for stroke prevention in patients with atrial fibrillation (spaf) and for prevention of venous thromboembolism (vte) in various patient populations, and 2) elinogrel, a direct-acting, reversible oral and i.v. adp receptor antagonist initially being developed for patients with acute coronary syndrome (acs).
Parole chiave per cercare:
biopharmaceutical company, innovative drugs, treatment of cardiovascular diseases, inflammatory diseases, betrixaban, factor xa inhibitor, stroke prevention, atrial fibrillation, prevention of venous thromboembolism, elinogrel, oral and i.v. adp receptor antagonist, acute coronary syndrome, antithrombotic, thrombosis, inflammatory diseases
Azienda Indirizzo :
4941 Page Ave,MICHIGAN CENTER,MI,USA
ZIP Code: Codice postale:
49254-1156
Numero di telefono :
5177640973 (+1-517-764-0973)
Numero di Fax :
5177645554 (+1-517-764-5554)
Sito web:
www. portola. com
Email:
USA codice SIC (Standard Industrial Codice di classificazione ) :
copia e incolla questa mappa google al tuo sito web o blog!
Premere il pulsante copia e incolla nel tuo blog o al sito web.
(Si prega di passare alla modalità ' HTML' , quando la pubblicazione nel tuo blog. Examples: WordPress Example, Blogger Example)